drugset
drugset / Trial / NCT00513851

Phase 1 Study of OSI-930 in Cancer Patients

NCT00513851 ↗

Phase 1 Completed 60 enrolled Astellas Pharma Inc OSI Pharmaceuticals · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Open label, phase 1, dose escalation

Timeline

Start
2006-04
Primary completion
2009-07
Completion
2009-09

Drugs

EvaluationDrugModalityDoseRoute
Subject OSI-930 Small molecule — Oral

Indications

No indication recorded.